Understanding Inhibitory Neurotransmission in Drug-Resistant Epilepsy
Functional Study of Inhibitory and Excitatory Neurotransmission in the Nervous Tissue Resected From Human Brain: Understanding New Molecular Mechanisms and Discovering New Therapeutic Targets to Cure Drug-resistant Epilepsy.
This study is testing how certain brain receptors work in people with drug-resistant epilepsy to see if new treatments can help manage their condition better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Neuromed IRCCS Academic / other |
| Locations | 1 site (Pozzilli, Isernia) |
| Trial ID | NCT05459090 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the functional alterations of GABA-A receptors in patients with drug-resistant temporal lobe epilepsy. The researchers will utilize patch-clamp recordings to characterize GABA-A mediated currents and identify the receptor subunit composition. Additionally, the study will explore the modulation of inhibitory neurotransmission through selective neuroactive molecules to enhance GABA release in the epileptic brain. The ultimate goal is to gain insights that could lead to new therapeutic strategies for managing epilepsy.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with drug-resistant temporal lobe epilepsy.
Not a fit: Patients whose temporal lobe epilepsy is caused by stroke, ischemia, cavernous angiomas, or meningiomas may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of novel treatments for patients with drug-resistant epilepsy.
How similar studies have performed: While the approach of modulating GABA-A receptor function is established, the specific focus on drug-resistant epilepsy and the proposed methodologies may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with drug-resistant temporal lobe epilepsy. Exclusion Criteria: * Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.
Where this trial is running
Pozzilli, Isernia
- IRCCS INM Neuromed — Pozzilli, Isernia, Italy (Recruiting)
Study contacts
- Principal investigator: katiuscia Martinello, Biology — Neuromed IRCCS
- Study coordinator: katiuscia Martinello, Biology
- Email: katiuscia.martinello@neuromed.it
- Phone: 0865915218
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.